ABSTRACT. Glucocorticoid therapy is frequently used in perinatology and neonatology for its beneficial pulmonary effects. We investigated the influence of neonatal glucocorticoid administration on brain damage caused by a concurrent episode of cerebral hypoxia-ischemia. Various doses of dexamethasone in several treatment schedules were administered to 7-d-old rats that were also subjected to unilateral cerebral hypoxia-ischemia. In 79% of control rats, a large unilateral cerebral infarction occurred, whereas all rats pretreated with dexamethasone in doses At present, glucocorticoids are frequently used in perinatal medicine, both antenatally to prevent respiratory distress syndrome by inducing fetal production of pulmonary surfactant and postnatally to improve lung function in infants with bronchopulmonary dysplasia after mechanical ventilation (1-4). Both groups of infants are at risk of experiencing episodes of cerebral hypoxia-ischemia either during or after glucocorticoid administration, due to con~plications of prematurity and neonatal intensive care.
At present, glucocorticoids are frequently used in perinatal medicine, both antenatally to prevent respiratory distress syndrome by inducing fetal production of pulmonary surfactant and postnatally to improve lung function in infants with bronchopulmonary dysplasia after mechanical ventilation (1-4). Both groups of infants are at risk of experiencing episodes of cerebral hypoxia-ischemia either during or after glucocorticoid administration, due to con~plications of prematurity and neonatal intensive care.
Glucocorticoids have long been used for the treatment of various neurologic disorders in the adult. Several beneficial effects of steroid therapy have been demonstrated. Treatment with veIy high doses of glucocorticoids (3-6 n~g/kg dexamethasone or 15-30 mg/kg methylprednisolone) have both reduced pathologic damage induced by experimental spinal cord trauma (5, 6) and improved neurologic outcome after human spinal cord injury (7) . Reductions in cerebral edema caused by tumors, infarction, pneumothorax, or convulsions with glucocorticoid therapy have also been reported (8) (9) (10) (11) (12) . However, until the present study, glucocorticoid therapy did not appear to be effective in reducing brain damage due to cerebral hypoxia-ischemia. Clinical (1 3-15) and experimental (1 6, 17) studies indicated that, in the adult, glucocorticoids are of no benefit or are detrimental (16, 17) for the treatment of a focal ischemic stroke or global cerebral ischemia.
In our study, we investigated the effect of glucocorticoid administration on the extent of brain damage produced in a perinatal model of cerebral hypoxia-ischemia in the rat (1 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The results demonstrate that in the neonate, rather than exacerbating neuronal damage, glucocorticoid administration before an episode of hypoxia-ischemia actually protects the brain from injury.
MATERIALS AND METHODS
Production of cerebral hypoxia-ischemia. Seven-d-old rats (Wistar or Sprague-Dawley) were anesthetized with halothane (4% for induction, 0.5-1% for maintenance) and the incision site was infiltrated with 2% lidocaine. The right carotid artery was isolated and ligated. A 3-h recovery period with the dam was followed by 3 h in 8% oxygen wit11 92% nitrogen in a plastic chamber inside a neonatal incubator with an air temperature of 37°C. This well-established model of pelinatal cerebral hypoxiaischemia reliably produces ipsilateral infarction of the striatum, thalamus, hippocampus, and overlying cortex (1 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The experimental protocol was approved by the Animal Care Committee of The Hospital for Sick Children.
Dexame~hasone administration. Either dexamethasone sodium phosphate or vehicle (Sabex Inc., Montreal, Quebec, Canada) was injected intraperitoneally in several dosage schedules. Dexamethasone hemisuccinate dissolved in normal saline by warming and sonication was also used in some initial experiments. Because there was no difference in results between animals treated with dexamethasone sodium phosphate and those treated with dexamethasone hemisuccinate, the phosphate salt was used for all subsequent experiments. Animals were drawn from multiple litters for all the treatment groups and concurrent control groups.
To mimic the chronic treatment of neonates with bronchopulmonary dysplasia (3, 4) daily doses of dexamethasone (0.5 mg/kg/d) were injected 48 h, 24 h and immediately before hypoxia-ischemia. In subsequent experiments, groups of animals received dexamethasone doses of 0.1,O.O 1,0.00 1, or 0.000 1 mg/ kg/d for 3 d. Next, the time required for dexamethasone to induce neuroprotection was investigated by administering a single dose of dexamethasone either 24 11, 3 h, or immediately before hypoxia. In addition, the effect of dexamethasone treatment posthypoxia was tested by injecting multiple doses of either 0.5 or 1.0 mg/kg/d immediately, 24 h, and 48 h after the end of hypoxia. Finally, the effect of a combination of treatment both pre-and postinsult was tested with a dexamethasone dose of 0. The presence or absence of gross cerebral infarction was noted on inspection of brains at the time of removal. In some animals, the extent of cerebral infarction was quantitated by measuring and comparing cross-sectional areas of brain regions ipsilateral and contralateral to the carotid ligation. Coronal sections were analyzed at I ) the level of the striatum anterior to the hippocampus and 2) the level of the dorsal hippocampus. A microcomputer image analysis system (MCID, Imaging Research Inc., Brock University, St. Catherine's, Ontario, Canada) was used to measure the cross-sectional area (excluding ventricles and cavitation) of the cerebral hemisphere, striatum, hippocampal formation, and neocortical mantle on the left and right sides.
Physiologic measurements. Dexamethasone administration influences many physiologic and biochemical processes. Therefore, several known systemic side effects of dexamethasone treatment (e.g. inhibition of somatic growth and hyperglycemia) were examined to determine to what degree these side effects occurred in our study.
Animals were weighed at the beginning of dexamethasone treatment, before hypoxia-ischemia, and before being killed at 14 d of age. Blood glucose was estimated before and after hypoxia in a subset of animals ( n = 67) using glucose oxidase reagent strips (Chemstrip bG, Boehringer Mannheim, Germany) interpreted visually after exposure to a drop of blood obtained from the tail vessels. The heart rate before, during, and after hypoxia was measured electrocardiographically in a subset ( n = 1 I) of treated (0.1 mg/kg/d) and control animals. The respiratory rate before, during, and after hypoxia was measured in a different subset ( n = 18) of treated and control animals. In addition, axillary temperature was measured in a subset of animals during hypoxia or near room temperature.
Statistical analysis.
All statistical analysis were performed with a microcomputer-based program (SAS, SAS Institute Inc., Cary, NC). Fisher's exact test was used for comparisons of gross pathology and mortality. Paired or unpaired t tests were used for comparisons of cross-sectional areas and heart rates. ANOVA with a Bonferroni correction for multiple comparisons was used to assess the significance of differences in weight and blood glucose.
RESULTS
Pretreatment with a hlgh dexamethasone dose. Dexamethasone pretreatment at 0.5 mg/kg/d for 3 d prevented brain damage associated with 3 h of cerebral hypoxia-ischemia in the neonatal rat. Cerebral infarction with gliosis or liquefaction ipsilateral to the carotid ligation occurred in the majority (31 of 39, or 79%) of control animals, but was absent in all dexamethasone-pretreated animals ( p < 0.001; Fig. I ). In control animals, there were marked reductions in the cross-sectional areas of cortex (56%), dorsal hippocampus (6 1 %), striatum (4 1 %), and hemisphere (40-48%) ipsilateral to the carotid ligation ( p < 0.001), whereas the two sides were indistinguishable in dexamethasonepretreated animals (Table 1 ; Fig. 2 ).
Pretreatment with lower dexamethasone doses. Dexamethasone pretreatment was observed to prevent brain damage over a wide dose range (Fig. 3) . Cerebral infarction did not occur in animals receiving a dose as low as 0.01 mg/kg/d ( p < 0.001).
Below this dose, the incidence of gross infarction did not differ from that of controls. The incidence of mortality during and after hypoxia did not differ between the control and dexamethasone-treated groups (Fig. 3) .
Pretreatment with a single dexamethasone dose. Hypoxicischemic brain damage could also be prevented with a single dose of dexamethasone, but this effect was dependent on the time interval between injection and hypoxia-ischemia. Dexamethasone (0.1 mg/kg) injected 24 h before the insult prevented cerebral infarction, but dexamethasone administered either immediately or 3 h before the insult had no such effect ( p < 0.00 1, Fig. 4 ). There was no difference in mortality during and after hypoxia between the control and single-dose treatment groups (Fig. 4) . sone treatment posthypoxia did not prevent brain injury. Gross unilateral cerebral infarction occurred in the majority of control and dexamethasone posttreated animals (Fig. 5) . Similarly, the reduction in cross-sectional areas ipsilateral to carotid ligation did not differ significantly between the dexamethasone posttreatment and control groups (Table I) . In contrast, a combination of pre-and posthypoxia dexamethasone treatment was neuroprotective (Fig. 5) .
Physiologic ejfects of dexamethasone treatment. The adminis-
tration of glucocorticoids at doses that were neuroprotective also produced a decrease in somatic growth. At the time of hypoxia, animals pretreated with dexamethasone (0.001 to 0.5 mg/kg/d for 3 d or 0.1 mg/kg for 24 h before hypoxia) weighed approximately 20% less than controls ( p < 0.05, ANOVA with Bonferroni correction, Fig. 6 ). However, by 7 d after hypoxia, only animals treated with dexamethasone posthypoxia still weighed significantly less than controls (50-58% of mean control weight of 25.2 + 0.7 g, p < 0.05, ANOVA).
Dexamethasone pretreatment also influenced systemic glucose metabolism during hypoxia. Before hypoxia, there was no significant difference in blood glucose between control animals and all dexamethasone-treated groups ( p > 0.05, ANOVA, mean control blood glucose, 5.4 + 0.3 mmol/L). However, after hypoxia, animals in most dexamethasone treatment groups were hyperglycemic compared to controls. Furthermore, an inverse relationship between posthypoxia blood glucose and incidence of cerebral infarction was observed (Figs. 3 and 4) .
No marked effect of dexamethasone on the cardiorespiratory function of neonatal rats could be demonstrated. Cardiac monitoring during hypoxia demonstrated that, although initial heart rates tended to be slightly less in dexamethasone-treated animals (0.1 mg/kg/d), these differences were not statistically significant (Fig. 7) . Furthermore, the heart rate changes during hypoxia were similar in dexamethasone-treated and control subjects (Fig. 7) .
Dexamethasone dose (mg/kgld) Fig. 3 . The effect of multiple doses of dexamethasone administered prehypoxia on pathology, mortality, and blood glucose. The incidence of gross cerebral infarction, which is presented as a percentage of survivors in each group (open hur.~), was dependent on the dose of dexamethasone injected daily (48, 24, and 0 h before hypoxia-ischemia). The mortality that occurred during and after hypoxia was similar in all groups (hatched burs, % of total n in parentheses). The levels of blood glucose measured immediately posthypoxia were elevated at the higher doses of dexamethasone treatment (closed sqzrare,, mean + SEM). *, p < 0.05; **, p < 0.001, different from vehicle (0 mg/kg/d). was similar in all groups. Blood glucose levels at the end of hypoxia were elevated in the group injected 24 h before hypoxia-ischemia (closed .sylrarcl.r, mean f SEM). *, p < 0.05; **, p < 0.00 1, different from groups injected 0 and 3 h prehypoxia. Fig. 5 . The effect on pathology and mortality of dexamethasone treatment posthypoxia-ischemia. The incidence of gross pathology (% survivors, open bars) was similar in animals posttreated with daily injections of vehicle or dexamethasone (0, 24, and 48 h after hypoxiaischemia). In contrast, gross cerebral infarction was prevented by dexamethasone treatment both pre-and posthypoxia-ischemia (0.1 mg/kg: -48, -24, 0, +24, and +48 h from the start of hypoxia-ischemia). Mortality (% total n in brackets, haiched bars) was similar in all groups. *, p < 0.05, different compared to vehicle (0 mg/kg/d).
Post-hypoxla dexamethasone dose
Respiratory rates, which varied from 80 to 180 breathslmin during hypoxia, were similar in dexamethasone-treated and control animals.
Axillary temperature during hypoxia-ischemia was similar in dexamethasone-and vehicle-treated animals. Within the hypoxia chamber (ambient temperature -37"C), axillary temperature was 39.2 f 0. Duration of hypoxia Fig. 7 . Effect of dexamethasone pretreatment on heart rate during hypoxia. Heart rate (mean -t SEM) was similar in dexamethasonepretreated (0.1 mg/kg/d) (hutched bars) and control animals (open burs) at all times points. temperature measured at an ambient temperature of -27°C was 34.7 _t 0.2 and 35.1 i 0.2"C in dexamethasone-(n = 9) and vehicle (n = 7)-treated animals, respectively.
DISCUSSION
Our results demonstrate that, in the neonatal period, treatment with dexamethasone before an episode of cerebral hypoxiaischemia provides a marked protection against brain damage. This dramatic effect of glucocorticoid treatment in the neonate was surprising in view of concerns about the negative effects of perinatal glucocorticoid therapy on the developing nervous system (2 1, 22) and the previous lack of success of glucocorticoids for the pre-or posttreatment of focal or global ischemia in the adult (13) (14) (15) (16) (17) . Furthermore, in neonatal rats, Altman et a/. (23) demonstrated that a single very large dose of dexamethasone (4 or 40 mg/kg) immediately before unilateral cerebral hypoxiaischemia was actually harmful in that it increased mortality. Indeed, based on such discouraging results from studies in the adult and neonate, glucocorticoid therapy was recently not recommended for the treatment of newborn infants with hypoxicischemic encephalopathy (24) . In agreement with several of these previous studies, our results demonstrate that posttreatment or immediate pretreatment with dexamethasone is ineffective in improving the pathology caused by an episode of perinatal cerebral hypoxia-ischemia. In contrast to findings in the adult, pretreatment with dexamethasone prevents hypoxic-ischemic brain damage in the neonate.
-
Our study also demonstrates several other unique aspects of glucocorticoid treatment. The neuroprotective effect of dexamethasone occurs not only at high doses, but also at doses much BARKS lower (e.g. 0.01 mg/kg/d) than those commonly used in glucocorticoid therapy for CNS trauma, edema, or hypoxia/ischemia (6, 9, 13, 15) . In addition, the results demonstrate that pretreatment with dexamethasone is ineffective if it is administered either immediately or 3 h before the hypoxic-ischemic incident, indicating that there is a latency of action of the relevant dexamethasone-induced effect of several hours.
The actual mechanism by which dexamethasone prevents neonatal hypoxic-ischemic brain damage cannot be determined from our data. However, of the many documented effects of dexamethasone treatment that have the potential to modify hypoxic-ischemic damage, several are unlikely to be involved in the neuroprotective action observed presently. Dexamethasone at very high doses has been reported to exert a stabilizing effect directly on the cell membrane (25). The latency of action of dexamethasone in the present study and its effectiveness at very low doses suggest that dexamethasone is not acting via a direct membrane effect but rather by inducing a biochemical or physiologic alteration at the cellular level that requires more than 3 h to become functional. Hypertension and bradycardia have been reported to occur in neonates that are treated with dexamethasone for bronchopulmonary dysplasia (26, 27). In the rats, there was no major difference in heart rate between glucocorticoid-or vehicle-treated animals, suggesting that dexamethasone is not preventing neonatal brain damage by a systemic circulatory effect. This is supported by preliminary results from studies in which we have measured cerebral blood flow after 3 h of hypoxia using autoradiographic techniques adapted for the 7-d-old rat (28). The data show that, in regions that are damaged in this model of hypoxia-ischemia (e.g. cerebral cortex, striatum and hippocampus), cerebral blood flow is reduced by 50-60% ipsilaterally in both dexamethasone-and vehicle-treated animals (unpublished experiments).
Additional available evidence indicates that other effects of glucocorticoid therapy can modify cerebral hypoxic-ischemic damage. For example, growth retardation, which occurred in dexamethasone-treated animals, has been shown by Trescher et a/. (29) to protect the developing nervous system from hypoxicischemic injury. Similarly, hyperglycemia, which exacerbates ischemic damage in the adult, has been shown to reduce or not alter hypoxic-ischemic injury in the immature brain (30-33). Although these effects may contribute to the response, neither hyperglycemia nor growth retardation alone were observed to confer as complete a cerebral protection as occurred with dexamethasone administration in our present study. Certainly, the fact that hyperglycemia and dexamethasone both influence hypoxic-ischemic brain damage differently in the immature compared to the adult animal suggests that the role of glucocorticoidinduced hyperglycemia should be investigated further. However, there are many differences between the neonate and the adult that could contribute to the differential age dependence of the glucocorticoid effects. Developmental changes in the hypothalamic-pituitary axis and glucocorticoid receptors occur in the first 2 wk of life (34), whereas within the brain there are marked increases in blood flow and cerebral glucose metabolism postnatally that may also alter glucocorticoid effects (35-37). Clearly, additional experiments are required to determine the mechanisms by which dexamethasone is affecting the response to hypoxia-ischemia.
Irrespective of the mechanisms involved, our study indicates that pretreatment with glucocorticoids at doses analogous to or less than those used to treat bronchopulmonary dysplasia protects the brain from damage due to perinatal hypoxia-ischemia. These data provide a further rationale for prenatal glucocorticoid administration to the fetus at risk of premature delivery and its complications, which include hypoxic-ischemic brain damage. Neurodevelopmental follow-up data from one controlled trial of dexamethasone for bronchopulmonary dysplasia indicate an improved outcome in steroid-treated infants (4), but neurosonography in another controlled trial of dexamethasone for bronchopulmonary dysplasia showed an increased incidence of periventricular leukomalacia in dexamethasone-treated infants (38). In view of increasing postnatal use of glucocorticoids in infants with bronchopulmonary dysplasia, our findings indicate that attention should be focused on the potential neuroprotective effects for neonates entered in controlled trials of glucocorticoids, who may continue to be at risk for hypoxic-ischemic brain injury due to the severity of their lung disease and other complications of neonatal intensive care.
